Nader Hirmas

Neu Isenburg, HE, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 35 publications

Clinical and Molecular Evaluation of HER2-Low and HER2-Ultralow Breast Cancer in the Penelope-B Clinical Trial Cohort.

Clinical and Molecular Evaluation of HER2-Low and HER2-Ultralow Breast Cancer in the Penelope-B Clinical Trial Cohort.

Journal: Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc

Published: November 05, 2025

Challenges and strategies for delivering effective breast cancer care in conflict zones.

Challenges and strategies for delivering effective breast cancer care in conflict zones.

Journal: Communications medicine

Published: October 07, 2025

Final survival results from the PENELOPE-B trial investigating palbociclib versus placebo for patients with high-risk HR+/HER2- breast cancer and residual disease after neoadjuvant chemotherapy.

Final survival results from the PENELOPE-B trial investigating palbociclib versus placebo for patients with high-risk HR+/HER2- breast cancer and residual disease after neoadjuvant chemotherapy.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: February 03, 2025

Head-to-head comparison of 68 Ga-FAPI-46 PET/CT, 18F-FDG PET/CT, and contrast-enhanced CT for the detection of various tumors.

Head-to-head comparison of 68 Ga-FAPI-46 PET/CT, 18F-FDG PET/CT, and contrast-enhanced CT for the detection of various tumors.

Journal: Annals of nuclear medicine

Published: September 10, 2024

Shifting the Paradigm: The Transformative Role of Neoadjuvant Therapy in Early Breast Cancer.

Shifting the Paradigm: The Transformative Role of Neoadjuvant Therapy in Early Breast Cancer.

Journal: Cancers

Published: September 05, 2024

Targeting PI3K inhibitor resistance in breast cancer with metabolic drugs.

Targeting PI3K inhibitor resistance in breast cancer with metabolic drugs.

Journal: Signal transduction and targeted therapy

Published: August 11, 2024

68Ga-Fibroblast Activation Protein Inhibitor PET/CT Improves Detection of Intermediate and Low-Grade Sarcomas and Identifies Candidates for Radiopharmaceutical Therapy.

68Ga-Fibroblast Activation Protein Inhibitor PET/CT Improves Detection of Intermediate and Low-Grade Sarcomas and Identifies Candidates for Radiopharmaceutical Therapy.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: December 15, 2023

Randomized Trial of Prostate-Specific Membrane Antigen PET/CT Before Definitive Radiotherapy for Unfavorable Intermediate- and High-Risk Prostate Cancer (PSMA-dRT Trial).

Randomized Trial of Prostate-Specific Membrane Antigen PET/CT Before Definitive Radiotherapy for Unfavorable Intermediate- and High-Risk Prostate Cancer (PSMA-dRT Trial).

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: November 03, 2023

Prognostic Implications of 68Ga-FAPI-46 PET/CT-Derived Parameters on Overall Survival in Various Types of Solid Tumors.

Prognostic Implications of 68Ga-FAPI-46 PET/CT-Derived Parameters on Overall Survival in Various Types of Solid Tumors.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: October 31, 2023

Diagnostic Accuracy of 68Ga-FAPI Versus 18F-FDG PET in Patients with Various Malignancies.

Diagnostic Accuracy of 68Ga-FAPI Versus 18F-FDG PET in Patients with Various Malignancies.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: September 08, 2023

Anti-hormonal maintenance treatment with the CDK4/6 inhibitor ribociclib after 1st line chemotherapy in hormone receptor positive / HER2 negative metastatic breast cancer: A phase II trial (AMICA).

Anti-hormonal maintenance treatment with the CDK4/6 inhibitor ribociclib after 1st line chemotherapy in hormone receptor positive / HER2 negative metastatic breast cancer: A phase II trial (AMICA).

Journal: Breast (Edinburgh, Scotland)

Published: July 05, 2023

68Ga-Labeled Fibroblast Activation Protein Inhibitor (68Ga-FAPI) PET for Pancreatic Adenocarcinoma: Data from the 68Ga-FAPI PET Observational Trial.

68Ga-Labeled Fibroblast Activation Protein Inhibitor (68Ga-FAPI) PET for Pancreatic Adenocarcinoma: Data from the 68Ga-FAPI PET Observational Trial.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: February 07, 2023

Showing 1-12 of 35

Last Updated: 09/26/2026